Lipocine is a biopharmaceutical company that develops oral drugs, with its lead product TLANDO licensed to partners for testosterone therapy. It last closed at $1.62 on Nov 17, down 2.41% on the day.
Only 1 firm rated LPCN in the past 90 days, not enough for a consensus
Average 12-month target
$4.00
▲ 146.9% upside
Based on 1 analyst who set a price target on LPCN in the past 90 days. The average target is $4.00, with a high of $4.00 and a low of $4.00, compared with the last close of $1.62.
Low $4.00Avg $4.00High $4.00
Blue marker: last close $1.62
Highest target$4.00
Average target$4.00
Lowest target$4.00
Latest rating changes
HC Wainwright & Co.Reiterated
Sep 21Hold$4
Date
Firm
Action
Rating
Price target
Sep 21
HC Wainwright & Co.
Reiterated
Hold
$4
Loading…
Technical Analysis
LPCN · as of the Nov 17 close · updated after every close
Downtrend
The stock sits between its 20 and 50 day averages. It is 110% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the swing low (Oct 12) at $1.59, and the nearest resistance the Pivot R1 at $1.66.
Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 7.5%/day
Key levels
$12.3752 week high+663.6%
$3.40200 day average+109.9%
$2.03100 day average+25.3%
$1.8350 day average+13.0%
$1.73Swing high (Nov 9)+6.8%
$1.66Pivot R1+2.5%
$1.62Pivot+0.0%
$1.62Last close
$1.59Swing low (Oct 12)−1.9%
$1.57Pivot S1−3.1%
$1.5420 day average−4.9%
$1.3852 week low−14.8%
Indicators
RSI (14)
48.00
Middle of its range
Neutral
MACD
-0.04
Above its signal line
Bullish
Stochastic
76.6
Middle of its range
Neutral
ADX (14)
15.5
No clear trend
Williams %R
-35.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
68.5
Oversold below −100, overbought above 100
Neutral
Rate of change
+11.0%
Change over 10 sessions
Bullish
ATR (14)
$0.12
Typical daily range, 7.5% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 25.5%/day
Key levels
$12.3752 week high+663.6%
$3.40200 day average+109.9%
$2.03100 day average+25.3%
$1.8350 day average+13.0%
$1.73Swing high (Nov 9)+6.8%
$1.66Pivot R1+2.5%
$1.62Pivot+0.0%
$1.62Last close
$1.59Swing low (Oct 12)−1.9%
$1.57Pivot S1−3.1%
$1.5420 day average−4.9%
$1.3852 week low−14.8%
Indicators
RSI (14)
35.79
Weak, oversold below 30
Neutral
MACD
-0.48
Above its signal line
Bullish
Stochastic
14.3
Near the bottom of its range
Oversold
ADX (14)
15.1
No clear trend
Williams %R
-86.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-94.1
Oversold below −100, overbought above 100
Neutral
Rate of change
−28.6%
Change over 10 sessions
Bearish
ATR (14)
$0.41
Typical daily range, 25.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LPCN
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how LPCN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow LPCN usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How LPCN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LPCN is in one of them and how their past LPCN trades turned out.
Lipocine is a biopharmaceutical company based in Salt Lake City, United States. It uses its own technology to develop medicines taken by mouth, including drugs that the body does not absorb well in standard form. Its lead product, TLANDO, is an oral treatment for testosterone deficiency in adult men, and partner companies sell it to patients in several countries. The company also develops candidates for brain and nervous system conditions, liver disease, and hormone treatments.